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IMPORTANCE Resveratrol, a polyphenol found in grapes, red wine, chocolate, and certain
berries and roots, is considered to have antioxidant, anti-inflammatory, and anticancer
effects in humans and is related to longevity in some lower organisms.
OBJECTIVE To determine whether resveratrol levels achieved with diet are associated with
inflammation, cancer, cardiovascular disease, andmortality in humans.
DESIGN Prospective cohort study, the Invecchiare in Chianti (InCHIANTI) Study (“Aging in the
Chianti Region”), 1998 to 2009 conducted in 2 villages in the Chianti area in a
population-based sample of 783 community-dwelling men and women 65 years or older.
EXPOSURES Twenty-four–hour urinary resveratrol metabolites.
MAIN OUTCOMES ANDMEASURES Primary outcomemeasurewas all-causemortality.
Secondary outcomes weremarkers of inflammation (serum C-reactive protein [CRP],
interleukin [IL]-6, IL-1β, and tumor necrosis factor [TNF]) and prevalent and incident cancer
and cardiovascular disease.
RESULTS Mean (95% CI) log total urinary resveratrol metabolite concentrations were 7.08
(6.69-7.48) nmol/g of creatinine. During 9 years of follow-up, 268 (34.3%) of the participants
died. From the lowest to the highest quartile of baseline total urinary resveratrol metabolites,
the proportion of participants who died from all causes was 34.4%, 31.6%, 33.5%, and 37.4%,
respectively (P = .67). Participants in the lowest quartile had a hazards ratio for mortality of
0.80 (95% CI, 0.54-1.17) compared with those in the highest quartile of total urinary
resveratrol in a multivariable Cox proportional hazards model that adjusted for potential
confounders. Resveratrol levels were not significantly associated with serum CRP, IL-6, IL-1β,
TNF, prevalent or incident cardiovascular disease, or cancer.
CONCLUSIONS AND RELEVANCE In older community-dwelling adults, total urinary resveratrol
metabolite concentration was not associated with inflammatory markers, cardiovascular
disease, or cancer or predictive of all-cause mortality. Resveratrol levels achieved with a
Western diet did not have a substantial influence on health status andmortality risk of the
population in this study.
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R esveratrol (3,5,4′-trihydroxystilbene), a polyphenolfound ingrapes, redwine, peanuts, chocolate, and cer-tain berries and Asiatic plant roots, has been shown to
exert anti-inflammatory effects in vitro and following supple-
mentation in animal models1,2 and to increase lifespan and
health inmice fed a high-calorie diet.3-6 Studies performed in
animalmodels have shown that resveratrol and other chemi-
cally relatedcompounds inhibit sirtuin 1 (SIRT1) andmimic the
effects of caloric restriction.6,7 In 1992, Siemann and Creasy8
postulated that the cardioprotective effects of redwine could
be attributed to resveratrol. The “French paradox,” in which
a low incidence of coronary heart disease occurs in the pres-
ence of a high dietary intake of cholesterol and saturated fat
inFrance,hasbeenattributed to the regular intakeof redwine9
and in particular, to resveratrol and other polyphenols con-
tained in wine.10
Somepreliminary evidence also suggests that resveratrol
in humansmay have anti-inflammatory effects, prevent can-
cer, diminish arterial stiffness, and improve endothelial reac-
tivity in older women.4-6 In a randomized trial of 20 healthy
adults, plasma concentrations of C-reactiveprotein (CRP) and
tumornecrosis factor (TNF)decreasedbyaboutone-thirddur-
ing 6 weeks of supplementation with a plant extract contain-
ing resveratrol.11 In addition, peripheral blood mononuclear
cell messenger RNA (mRNA) expression of interleukin (IL)-6
andTNFdecreased in the group receiving resveratrol over the
same intervention period. In a small crossover trial, a supple-
ment containing resveratrol and polyphenols from musca-
dine grape suppressed the increase of IL-1β following a high-
fat,high-carbohydratemeal.12Arecentphase2studyofSRT501,
a micronized oral formulation of resveratrol that activates
SIRT1, in multiple myeloma patients was halted early owing
to a high level of adverse effects and renal failure.13
Although resveratrol has attracted agreat deal of attention
owing to its effects on inflammation, carcinogenesis, and lon-
gevity in vitro or in lower organisms, and in trials involving su-
praphysiologicdosesof resveratrol inhumans, there is littleepi-
demiologicdata to support a linkbetweenphysiologic levelsof
resveratrol achieved with the diet alone and health in hu-
mans. Some of the challenges in studying resveratrol in hu-
mans are the rapid uptake, metabolism, and excretion of res-
veratrolandthe lowconcentrations found inplasma.4Recently,
mass spectrometric methods have been developed that allow
insights into resveratrol metabolism in humans through the
measurementof resveratrolmetabolites inurine.14Wehypoth-
esized that higher urinary concentrations of resveratrol me-
tabolites were associated with reduced risk of all-cause mor-
tality and associated with lower inflammation and lower
prevalence and incidence of cardiovascular disease and can-
cer. To test these hypotheses, we measured urinary metabo-
lites of resveratrol in a population-based cohort study.
Methods
Study Population
Thestudyparticipantsweremenandwomen,65yearsorolder,
who participated in the Invecchiare in Chianti, “Aging in the
Chianti Area” (InCHIANTI) Study, conducted in 2 small towns
in Tuscany, Italy. The rationale, design, and data collection
methods have been described elsewhere,15 and themain out-
come of this longitudinal study is mobility disability. Briefly,
in August 1998, 1270 people 65 years or older were randomly
selected fromthepopulationregistryofGreve inChianti (popu-
lation, 11 709) and Bagno a Ripoli (population, 4704), and of
1256 eligible subjects, 1155 (90.1%) agreed to participate. Par-
ticipants received an extensive description of the study and
participatedafterwritten, informedconsentwasobtained.The
study protocol compliedwith theDeclaration of Helsinki and
was approvedby the ItalianNational Institute ofResearch and
Care on Aging Ethical Committee and by the Institutional Re-
view Board of the Johns Hopkins University School of Medi-
cine. InCHIANTIStudyparticipantswereevaluated for a3-year
follow-up visit from 2001 to 2003 (n = 926), a 6-year fol-
low-up visit from 2004 to 2006 (n = 844), and 9-year fol-
low-up visit from 2007 to 2009 (n = 768).
Data Collection and Definition
Data on demographic characteristics, lifestyle factors, and
medication use were collected using standardized question-
naires. Smokinghistorywasdeterminedfromself-report.Daily
alcohol intake, expressed in gramsper day, and resveratrol in-
take, expressed inmilligramsperday,weredeterminedat each
study visit from participants answers to the European Pro-
spective Investigation into Cancer and Nutrition (EPIC) food
frequencyquestionnaire,whichhasbeenvalidated in the Ital-
ian population.16 Educationwas recorded as number of years
of school.
All participantswere examined in a standardizedmanner
by a study geriatrician. Diseases were ascertained according
to standard, preestablished criteria and algorithms similar to
those used in theWomen’s Health andAging Study for diabe-
tes mellitus, coronary heart disease, chronic heart failure,
stroke, and cancer.17 The algorithm for the diagnosis of dia-
betes was based on the use of insulin and oral hypoglycemic
agents and on responses to a questionnaire administered to
the primary care physician of the studyparticipant.17 Systolic
and diastolic blood pressures were calculated as the mean of
3measures takenwith a standardmercury sphygmomanom-
eter during thephysical examination.Weight andheightwere
measuredusingahigh-precisionmechanical scale. Bodymass
index (BMI) was calculated asweight in kilograms divided by
height in meters squared. The Mini-Mental State Examina-
tion (MMSE) was administered at enrollment, and an MMSE
score lower than 24 was considered consistent with cognitive
impairment.18 Chronic kidney disease was defined as esti-
mated glomerular filtration rate of less than 60 mL/min/1.73
m2 using the 4-variable Chronic Kidney Disease–Epidemiol-
ogy Collaboration equation of Levey and colleagues.19
Mortality datawere collected using data from theMortal-
ityGeneralRegistrymaintainedby theTuscanyRegion.Analy-
ses include those who refused to participate in the follow-up
after baseline and thosewhomoved away butwere known to
bealiveat the timeofcensoringof thisanalysis.Causesofdeath
werenot available for all participantswhodiedbecause cause-
specific data have not yet been released by the Tuscany re-
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gional authorities. Therefore, the analysis in thepresent study
uses all-cause mortality.
Laboratory Studies
Twenty-four–hour urine sampleswere collected frompartici-
pants at baseline. Urine sampleswere then aliquoted and im-
mediately stored at −80°C. Of the 1155 adults 65 years or older
whoenrolled in thestudy,783had24-hoururinesamplesavail-
able formeasurements of resveratrol. Resveratrol conjugates
derived fromgut andmicrobialmetabolismweremeasured in
24-hour urine samples using liquid chromatography–tandem
mass spectrometry (LC-MS/MS).14 Briefly 1 mL of urine with
the internal standard was loaded into a previously equili-
brated Oasis (Waters) HLB (hydrophilic-lipophilic-balanced)
solid-phase extraction 96-well plate (30 mg). Urinary resve-
ratrol metabolites were eluted with acidified methanol solu-
tionandethyl acetate.After evaporation, the sampleswere re-
constitutedwith 100μLof themobilephaseand thenanalyzed
by liquid chromatography (PerkinElmer S200) coupled to a
triple-quadrupolemass spectrometer (API3000; AppliedBio-
systems) as described elsewhere.14 Theoverall time takenper
samplewas about 14-minutes, including the cleanupby solid-
phase extraction, optimized runtime by liquid chromatogra-
phy, andmass spectrometrydetection.14 Intra-batchand inter-
batch coefficients of variation were less than 10.5% and less
than 10.7%, respectively. Becausewewereuncertainwhether
all the participants collected urine for a full 24-hour period,
all results for urinary resveratrol metabolites were corrected
for creatinine. Urinary creatininewasmeasured by themodi-
fied Jaffe method,20 and results for 24-hour urinary resve-
ratrolmetabolites are reported as nanomoles per gramof cre-
atinine.
SerumCRP, IL-6, IL-1β, and TNFweremeasured in dupli-
cate by high-sensitivity enzyme-linked immunosorbent as-
says (ELISA) using commercial kits (BioSource Interna-
tional), as described in detail elsewhere.21 Commercial
enzymatic tests (RocheDiagnostics)were used formeasuring
serum total cholesterol, triglycerides, and high-density lipo-
protein (HDL) cholesterol concentrations. Low-density lipo-
protein (LDL) cholesterol level was calculated using the Frie-
dewald formula.22Plasmaglucoseconcentrationwasmeasured
by the glucose oxidase method (Beckman Instruments Inc).
Normal, impaired, anddiabetic fasting glucose levelswere set
at fasting plasma glucose levels of 99 mg/dL or lower, 100 to
125 mg/dL, and higher than 125 mg/dL, respectively.23
Statistical Analysis
Variables are reported asmeans (SDs) or as percentages. Vari-
ables that were highly skewed (ie, markers of inflammation)
were log-transformed to achieve a normal distribution. Char-
acteristics of subjects were compared across quartiles of uri-
nary resveratrolmetabolitesusingKruskal-Wallis tests for con-
tinuous variables and χ2 tests for categorical variables.
Spearmancorrelationwasused toexamine the relationshipbe-
tweenalcohol intake andurinary resveratrolmetabolites. Cox
proportional hazards models were used to examine the rela-
tionshipbetweenquartile of total urinary resveratrolmetabo-
lites and all-causemortality, incident cardiovascular disease,
and incident cancer over 9 years of follow-up. Multivariable
Cox proportional hazards models were adjusted for age, sex,
BMI, and thenother variables thatwere significant in theuni-
variate analyses. All analyseswere performed using SAS soft-
ware, version 9.1.3 (SAS Institute) with a type I error of 0.05.
Results
Overall, mean (95% CI) log total urinary resveratrol metabo-
lite concentrations were 7.08 (6.69-7.48) nmol/g of creati-
nine. Less than 1%of the studypopulation reportedusing any
typeof nutritional supplement. The characteristics of thepar-
ticipants across quartiles of total urinary resveratrol metabo-
lite concentrations are listed in Table 1. There were signifi-
cantly more men in the highest quartiles of total urinary
resveratrolmetabolites. Alcohol consumption, current smok-
ing, and physical activity were higher among participants in
the highest quartile of total urinary resveratrol metabolites
comparedwith the lower quartiles. The proportion of partici-
pants with abnormal fasting plasma glucose levels was sig-
nificantly different across quartiles, with the highest propor-
tionofsubjectswithdiabetic fastingglucose levels in the lowest
andhighest quartiles. Theproportionofparticipantswith cog-
nitive impairment (MMSE score <24) was significantly lower
in the participants in the highest quartile of total urinary res-
veratrol metabolites. There were no significant differences
across thequartilesof total urinary resveratrolmetabolite con-
centrationsbyage, education,BMI,CRP, IL-6, IL-1β,TNF,mean
arterial bloodpressure, total cholesterol,HDLcholesterol, LDL
cholesterol, triglycerides, or by prevalence of hypertension,
heart failure, peripheral artery disease, stroke, cancer, and
chronic kidneydisease. Theprevalenceof coronary arterydis-
easeanddiabeteswerehigher among those in the lowestquar-
tile of total urinary resveratrolmetabolites. TheSpearmancor-
relation between alcohol consumption in grams per day and
total urinary resveratrol metabolite concentrations was 0.67
(P < .001).
We compared the characteristics of the 782 participants
with resveratrolmeasurementswith the 273participantswho
had no resveratrol measurements at baseline. The partici-
pants with no resveratrol measurements had a significantly
higher proportion with cognitive impairment (MMSE score
<24), stroke, lower physical activity, andmortality compared
withparticipantswhohadresveratrolmeasurements.Theyalso
had lower levels of total cholesterol and higher levels of IL-1β
andTNF comparedwith the participantswhohad resveratrol
measurements. There were no significant differences in age,
education, BMI, smoking, chronic disease, or other variables
as, detailed in Table 1 between thosewith andwithout resve-
ratrol measurements.
During 9 years of follow-up, 268 (34.2%) of the partici-
pants died. There were no significant differences in the pro-
portion of participants who died across quartiles of total uri-
nary resveratrol metabolite concentrations. The baseline
characteristics of the participants by vital status during fol-
low-up are listed inTable 2. Participantswhodiedwere older,
more likely tobemale,with lowereducation, lowerBMI,physi-
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cally inactive,withdiabetic fastingplasmaglucose andhigher
CRP, IL-6, andTNFconcentrations, highermeanarterial blood
pressure, and lower total, HDL, and LDL cholesterol levels. A
higher proportion of those who died hadMMSE scores lower
than 24, heart failure, peripheral artery disease, stroke, dia-
betes, and chronic kidney disease. There were no significant
differences between participants who died during the study
period and thosewhodidnot in alcohol intake, current smok-
ing, gut resveratrolmetabolites,microbial resveratrolmetabo-
lites, total urinary resveratrol metabolites, IL-1β, triglycer-
ides, coronary artery disease, or cancer.
The relationship between total urinary resveratrol me-
tabolites and all-cause mortality was examined using multi-
variable Coxproportional hazardsmodels (Table 3). Total uri-
nary resveratrol metabolites concentration was not
significantly associatedwithmortality inmodels adjusting for
age, sex,BMI, serumlevelsof lipids, chronicdiseases,andother
variables. The relationship between total urinary resveratrol
metabolites andmortality did not change in additional mod-
els that included markers of inflammation in addition to the
covariates used in the final models (data not shown). Sensi-
tivity analyseswere conducted to take into considerationmor-
Table 1. Baseline Characteristics of Study Participants by Quartiles of Total Urinary Resveratrol Metabolitesa
Characteristic
Quartiles of Total Urinary Resveratrol Metabolites, nmol/g of
Creatinine
P Valueb
<1554
(n = 195)
1554-4996
(n = 196)
>4996-15 010
(n = 196)
>15 010
(n = 196)
Age, mean (SD), y 75.2 (7.5) 74.3 (7.0) 74.5 (7.0) 73.8 (6.2) .52
Sex
Male 28.7 33.2 48.2 68.7
<.001
Female 71.3 66.8 51.8 31.3
Education, mean (SD), y 5.0 (2.6) 5.1 (3.1) 5.6 (3.8) 5.8 (3.4) .14
Alcohol intake, mean (SD),
g/d
2.4 (5.8) 8.8 (15.9) 16.3 (16.0) 31.1 (24.7) <.001
Consumes alcohol 37.4 66.8 87.8 99.0 <.001
Current smoker 7.7 12.8 8.6 25.1 <.001
BMI, mean (SD) 27.5 (4.2) 27.7 (4.1) 27.5 (3.8) 27.3 (4.0) .48
Physical activity
Inactive 24.6 17.9 17.9 15.0
.002Low 44.6 51.3 41.8 36.8
Moderate-high 30.8 30.8 40.3 48.2
Fasting plasma glucose
Normal 72.8 80.1 75.1 69.7
.05Impaired 15.9 12.8 18.8 15.9
Diabetic 11.3 7.1 6.1 14.4
Log, mean (SD)
CRP, μg/mL 1.09 (1.07) 1.08 (0.98) 0.97 (1.04) 0.99 (1.01) .52
IL-1β, pg/mL −2.15 (1.30) −2.19 (1.14) −2.24 (1.22) −2.25 (0.92) .24
IL-6, pg/mL 1.08 (0.55) 1.06 (0.50) 1.16 (0.58) 1.17 (0.57) .18
TNF, pg/mL 1.47 (0.59) 1.43 (0.52) 1.45 (0.54) 1.54 (0.78) .59
Mean arterial BP, mm Hg 105 (11) 106 (11) 105 (10) 106 (12) .78
Cholesterol, mean (SD),
mg/dL
Total 215 (37) 223 (41) 219 (42) 220 (38) .28
HDL 56 (14) 56 (15) 55 (16) 58 (15) .45
LDL 133 (31) 142 (36) 138 (37) 138 (34) .16
Triglycerides 130 (79) 132 (63) 128 (73) 123 (57) .20
MMSE score <24 32.8 31.1 31.0 16.4 <.001
Hypertension 48.2 50.5 44.2 47.7 .65
Coronary artery disease 6.7 1.5 7.1 3.6 .03
Heart failure 6.7 3.1 4.6 3.6 .32
Peripheral artery disease 6.2 4.6 4.1 7.7 .40
Stroke 4.1 3.1 5.6 3.1 .53
Diabetes mellitus 15.9 10.2 9.1 18.5 .02
Cancer 7.7 6.1 7.6 3.4 .30
Chronic kidney disease 27.2 23.0 20.3 16.4 .07
Died during follow-up, overall 34.4 31.6 33.5 37.4 .67
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
BP, blood pressure; CRP, C-reactive
protein; HDL, high-density
lipoprotein; IL, interleukin; LDL,
low-density lipoprotein; MMSE,
Mini-Mental State Examination18;
TNF, tumor necrosis factor.
SI conversion factors: To convert
ethanol to moles, multiply by 0.0217;
total cholesterol, HDL cholesterol,
and LDL cholesterol to millimoles per
liter, multiply by 0.0259; triglycerides
to millimoles per liter, multiply by
0.0113; CRP tomicromoles per liter,
multiply by 9.524; IL-6 tomicromoles
per liter, multiply by 0.131.
a Unless otherwise indicated, data are
reported as percentage of
participants.
bKruskal-Wallis test for continuous
variables and χ2 test for categorical
variables.
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tality in the first year following resveratrolmeasurements, be-
cause those who died within the first year may have been ill
at the time of resveratrol measurements, and potential ef-
fects of excessive alcohol consumption, since resveratrolwas
strongly associatedwith alcohol intake, as shownpreviously.
Inanalternativeanalysis, 12participantswhodiedwithin1year
of enrollment were excluded. Total urinary resveratrol me-
tabolites were not significantly related to all-cause mortality
inmultivariableCoxproportionalhazardsmodels adjusting for
the samecovariates as themodels inTable 3 (datanot shown).
Inanother analysis, 40participantswereexcludebecause they
consumed more than 4 drinks (>56 g or ethanol) per day (1
drink = 14 g of ethanol). Total urinary resveratrolmetabolites
were not significantly related to all-cause mortality in multi-
variable Cox proportional hazards models adjusting for the
same covariates as the models in Table 3 (data not shown).
To corroborate the relationship between urinary resve-
ratrolmetabolites and all-causemortality further, we also ex-
amined the relationship of dietary intake of resveratrol with
all-causemortality. In the 783participants, themean (95%CI)
of logdietary intakeof resveratrol inwas−2.42 (−2.55 to−2.28)
mg/d.TheSpearmancorrelationbetweendietary intakeof res-
veratrol and total resveratrol metabolites was 0.67 (P < .001).
The relationshipbetweendietary intakeof resveratrol andall-
causemortalitywas examined using amultivariable Cox pro-
portional hazardsmodelwith the same covariates as in the fi-
Table 2. Baseline Characteristics of Study Participants by Vital Status During 9 Years of Follow-upa
Characteristic
Died
(n = 268)
Alive
(n = 515) P Valueb
Age, mean (SD), y 79.3 (7.2) 71.9 (5.3) <.001
Sex
Male 51.1 41.4
.01
Female 48.9 58.6
Education, mean (SD), y 4.6 (2.9) 5.8 (3.4) <.001
Alcohol intake, mean (SD), g/d 13.4 (16.7) 15.3 (21.6) .91
Current smoker 16.0 12.2 .14
BMI, mean (SD) 26.9 (4.1) 27.8 (4.0) .002
Physical activity
Inactive 34.6 1.7
<.001Low 41.0 45.0
Moderate-high 24.4 44.3
Fasting plasma glucose
Normal 72.0 75.7
.04Impaired 14.6 16.5
Diabetic 13.4 7.8
Log, mean (SD)
Gut RMs, nmol/g of creatinine 2.29 (8.93) 1.51 (9.06) .08
Microbial RMs, nmol/g of creatinine 5.72 (7.16) 6.59 (5.90) .91
Total urinary RMs, nmol/g of creatinine 6.69 (6.40) 7.29 (5.21) .51
CRP, μg/mL 1.23 (1.10) 0.92 (0.97) <.001
IL-1β, pg/mL −0.28 (1.21) −2.17 (1.12) .13
IL-6, pg/mL 1.30 (0.59) 1.02 (0.51) <.001
TNF, pg/mL 1.57 (0.58) 1.43 (0.63) <.001
Arterial BP, mean (SD), mm Hg 107 (11) 105 (11) .01
Cholesterol, mean (SD), mg/dL
Total 211 (41) 224 (38) <.001
HDL 55 (17) 56 (14) .07
LDL 130 (35) 141 (34) <.001
Triglycerides 129 (70) 128 (68) .64
MMSE score <24 41.8 20.6 <.001
Hypertension 50.8 46.0 .21
Coronary artery disease 4.9 4.7 .91
Heart failure 9.0 2.1 <.001
Peripheral artery disease 12.7 1.9 <.001
Stroke 7.8 1.9 <.001
Diabetes mellitus 16.8 11.7 .05
Cancer 7.8 5.4 .19
Chronic kidney disease 31.3 16.7 <.001
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
BP, blood pressure; CRP, C-reactive
protein; HDL, high-density
lipoprotein; IL, interleukin; LDL,
low-density lipoprotein; MMSE,
Mini-Mental State Examination18;
RMs, resveratrol metabolites; TNF,
tumor necrosis factor.
SI conversion factors: To convert
ethanol to moles, multiply by 0.0217;
total cholesterol, HDL cholesterol,
and LDL cholesterol to millimoles per
liter, multiply by 0.0259; triglycerides
to millimoles per liter, multiply by
0.0113; CRP tomicromoles per liter,
multiply by 9.524; IL-6 tomicromoles
per liter, multiply by 0.131.
a Unless otherwise indicated, data are
reported as percentage of
participants.
bKruskal-Wallis test for continuous
variables and χ2 test for categorical
variables.
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nal model in Table 3. Compared with the highest quartile of
resveratrol intake, thehazard ratios (95%CIs) forall-causemor-
tality in the lowest (first), second, and third quartiles of res-
veratrol were 1.17 (0.75-1.81), 1.29 (0.84-1.99), and 1.42 (0.97-
2.09), respectively, after adjusting for age, sex, education,BMI,
physicalactivity, totalenergy intake, totalcholesterol,HDLcho-
lesterol,MMSEscore,meanarterialbloodpressure,andchronic
diseases.
Sincedietary intakeof resveratrol could changeover time,
weassesseddietary resveratrol intake in608, 517, and434par-
ticipants seen at the 3-, 6-, and9-year follow-upvisits, respec-
tively. Themean (95%CI) log findings of dietary intake of res-
veratrol at the 3-, 6-, and 9-year follow-up visits were −2.71
(−2.87 to−2.55),−2.82 (−2.99to−2.64), and−2.66 (−2.81 to−2.50)
mg/d, respectively. The intra-class correlation of dietary in-
take of resveratrol over the 9-year follow-up period was 0.52.
The Spearman correlations between dietary resveratrol in-
take at the 3-, 6-, and 9-year follow-up visits and urinary res-
veratrol concentrations at baseline were 0.59 (P < .001), 0.56
(P < .001), and 0.45 (P < .001), respectively.
Of 639 participants who were free of cardiovascular dis-
ease at enrollment, 174 (27.2%) developed cardiovascular dis-
easeduring follow-up.Theproportionsofparticipantswith in-
cident cardiovascular disease from the lowest to the highest
quartiles of resveratrolwere 22.3%, 29.6%, 28.4%, and 28.0%,
respectively (P = .44).Of734participantswhowere freeof can-
cer at enrollment, 34 (4.6%) developed cancer during follow-
up. Theproportions of participantswith incident cancer from
the lowest to the highest quartiles of resveratrol were 4.4%,
4.9%, 5.0%, and 4.3%, respectively (P = .98).
Discussion
The present study shows, contrary to all our hypotheses, that
urinary resveratrol metabolites are not predictive of longev-
ity in older community-dwelling adults and, in addition, are
not significantly associated with markers of inflammation,
prevalent or incident cardiovascular disease, or cancer. Res-
veratrol levels achievedwith the diet do not show any appar-
ent protective association with disease and markers of dis-
ease in humans and are not associated with lifespan. To our
knowledge, this is the first large, observational epidemio-
logic study to examine the relationship between urinary res-
veratrol from normal dietary intake and health outcomes in
humans. Toour knowledge, nourinary resveratrol concentra-
tion has been established as an effective threshold in hu-
mans. Therefore, we analyzed urinary resveratrol concentra-
tions as quartiles, as has been done in a previous study of
resveratrol and health outcomes.24
The strengths of the study are the population-based sam-
pling, the strict criteria for assessment of chronic diseases in
the cohort, lowuseofnutritional supplements (<1%), themea-
surement of multiple biomarkers for inflammation, the high
follow-up rates, and the availability of 9 years of data from
monitoringofvital events. In addition,urinary resveratrolme-
tabolites were measured in urine samples that had been col-
lected over a 24-hour period. Urinary resveratrol levels in the
present study are similar to those reported elsewhere.25 The
lack of an association between resveratrol, health, and lon-
gevity might be owing to variability in resveratrol intake in a
population that has a large variability in exposure to resve-
ratrol, interindividual variation, and variability of host-gut
microbiota,26,27whichmight imply that amuch larger sample
size would be needed to detect the association.
Although annual sales of resveratrol supplements have
reached $30million in the United States alone,28 there is lim-
ited and conflicting human clinical data demonstrating any
metabolic benefits of resveratrol, and there are no data con-
cerning its safety in high doses or for long-term supplemen-
tation in older people, who often have multiple comorbidi-
ties for which they are taking multiple medications.
Supraphysiologic doses of resveratrol (100 mg) from Asiatic
roots have been shown to decrease circulating levels or ex-
pressionofCRP, IL-6, TNF, and IL-1β inhuman trials.11,12 In ad-
dition, recent trials show that supplementation for 1 yearwith
lower doses of resveratrol (8 mg) decreased levels of CRP,
TNF-α, IL-6/IL-10 ratio and increased levels of the anti-
inflammatory cytokine IL-10 in 75 subjectswith cardiovascu-
lar risk factors.29 Another study of resveratrol, 150 mg/d ad-
Table 3. Relationship Between Total Urinary Resveratrol Metabolites and All-CauseMortality in SeparateMultivariable Cox
Proportional HazardsModels
Covariates in Models
Quartiles of Total Urinary Resveratrol Metabolites, nmol/g creatininea
P Valueb<1554 1554-4996 >4996-15 010 >15 010
Age, sex 0.83 (0.58-1.17) 0.95 (0.67-1.36) 0.75 (0.53-1.05) 1 [Referent] .55
Age, sex, education, BMI, physical activity, total
cholesterol, HDL cholesterol, MMSE score
0.74 (0.51-1.08) 0.90 (0.62-1.30) 0.71 (0.49-1.02) 1 [Referent] .30
Age, sex, education, BMI, physical activity, total
cholesterol, HDL cholesterol, MMSE score, mean
arterial BP, and chronic diseasesc
0.80 (0.54-1.17) 1.03 (0.70-1.51) 0.84 (0.58-1.22) 1 [Referent] .43
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); BP, blood pressure; HDL, high-density
lipoprotein; MMSE, Mini-Mental State Examination.18
SI conversion factors: To convert ethanol to moles, multiply by 0.0217; total
cholesterol, HDL cholesterol, and LDL cholesterol to millimoles per liter,
multiply by 0.0259; triglycerides to millimoles per liter, multiply by 0.0113; CRP
tomicromoles per liter, multiply by 9.524; IL-6 tomicromoles per liter, multiply
by 0.131.
a Unless otherwise indicated, data are reported as hazards ratios (95% CIs) for
each quartile of urinary resveratrol metabolites relative to the highest quartile
(Referent).
b For trend across quartiles.
c Chronic diseases include coronary heart disease, heart failure, stroke,
peripheral artery disease, diabetes, cancer, and chronic kidney disease.
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ministered for 30 days to healthy obese men, did not find
significant changes to circulating CRP, IL-6, IL-1β, and IL-18,
but there was a reduction in TNF concentrations.30
In thepresent studyof community-dwelling older adults,
therewereno significant associations betweenurinary resve-
ratrol metabolites and serum CRP, IL-6, IL-1β, or TNF. A pre-
vious study showed that resveratrol supplementation de-
creased fasting plasma glucose levels in adults with type 2
diabetes31 and in healthy obese men.30 Resveratrol supple-
mentationdecreasedLDL cholesterol levels in patients recov-
ering frommyocardial infarction.32 In 75patientswith cardio-
vascular disease, supplementation with grape extract for 6
monthsdecreasedoxidizedLDLandApoB levels.33 In thepres-
ent study, there was no significant relationship between uri-
nary resveratrol metabolites and total cholesterol, HDL cho-
lesterol, LDL cholesterol, or triglycerides.
On theotherhand, there are trialswith resveratrol that re-
ported negative results. A trial of resveratrol-enriched grape
extract supplementation for 1 year in hypertensive men with
type 2 diabetes mellitus showed no impact of resveratrol on
blood pressure, glucose, and lipids, but there was a signifi-
cant reduction in serum IL-6 and alkaline phosphatase levels
and reduction of the expression of proinflammatory cyto-
kinesCCL3, IL-1β, andTNF.34Resveratrol supplementationdid
not change body composition, restingmetabolic rate, plasma
lipids, or inflammatory markers in a randomized, double-
blind, placebo-controlled trial in nonobese womenwith nor-
mal glucose tolerance.33 In addition, resveratrol didnot affect
its putativemolecular targets, including SIRT1, in either skel-
etalmuscle or adipose tissue. In a randomized, double-blind,
placebo-controlled trial, high-dose resveratrol supplementa-
tion had no effect on glucosemetabolism, insulin sensitivity,
restingenergyexpenditure, or inflammatorymarkers inobese
men.35
Resveratrol isonlyoneofmanypolyphenols thatare found
in red wine and grapes. In the present study, urinary resve-
ratrol levels were significantly associated with alcohol in-
take.The studypopulation is located in thewine-growingChi-
anti region of Tuscany. The moderately high correlation
between alcohol intake and urinary resveratrol is most likely
attributed to a correlation between wine intake and resve-
ratrol.Aprevious studyhas shownthaturinary resveratrol lev-
els are avalidbiomarker ofwine consumption.25Humanstud-
ies of the oral absorption of 14C-resveratrol show that the
elimination half-life of total resveratrol metabolites is about
6 to 15hours after oral doses.36 Resveratrolmetabolites canbe
detected in the urine of humanswho consume 1 glass ofwine
per week if the last drinkwas consumed 3 days previously, or
in those who consume 3 glasses of wine per week if the last
drink was consumed 5 days previously.25
Conclusions
In conclusion, this prospective study of nearly 800 older com-
munity-dwellingadults showsnoassociationbetweenurinary
resveratrolmetabolites and longevity.This studysuggests that
dietary resveratrol fromWesterndiets in community-dwelling
older adults does not have a substantial influence on inflam-
mation, cardiovascular disease, cancer, or longevity.
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